Clinical trials: Prostate Disease
Prostate Cancer
PK and Dose Escalation and Expansion Study of DST-2970
This is a Phase I multi-center, open-label, study of DST-2970 to determine the MTD, overall safety/tolerability, PK/pharmacodynamic parameters, and efficacy in prostate cancer patients.The study will include a dose escalation…
- Trial name
- NCT04291664
- Testing
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- DisperSol Technologies, LLC
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Prostate Cancer
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer
Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer
- Trial name
- Sorse (NCT00668083)
- Where
- 12 sites in Italy
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Benign Prostatic Hyperplasia
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.
- Trial name
- NCT00918983
- Testing
- NX-1207
- Where
- 41 sites in United States
- Volunteers
- 500 people
- Sponsor
- Nymox Corporation
Prostate Cancer
Comprehensive Assessment of Cancer Theranostic Response
The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study.
- Trial name
- TRAQinform (NCT06815354)
- Testing
- TRAQinform Theranostics
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- AIQ Solutions
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Benign Prostatic Hyperplasia (BPH)
Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)
The HistoSonics' Histotripsy BPH Device, the Vortx Rx, is a portable ultrasound therapy device. The purpose of this study is to assess and monitor the performance of the Vortx Rx for initial safety and efficacy for the treatment…
- Trial name
- NCT01775488
- Testing
- Vortx Rx - Histotripsy BPH Device
- Sponsor
- HistoSonics, Inc.
Prostatic Neoplasms
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA).
- Trial name
- NCT02034552
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone acetate, Prednisone
- Where
- 19 sites in United States
- Volunteers
- 68 people
- Sponsor
- Bayer
Benign Prostatic Hyperplasia
RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up
The objective of the RELIEF Study is to compare the safety, effectiveness and patient experience outcomes in real-world subjects treated with different modalities for symptomatic BPH.
- Trial name
- RELIEF (NCT05784558)
- Testing
- UroLift System, Watchful Waiting or BPH Medications, Other Surgical Intervention
- Where
- United States
- Sponsor
- NeoTract, Inc.
Prostate Cancer
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer.
- Trial name
- NCT00116155
- Testing
- CV787 (CG7870)
- Sponsor
- Cell Genesys
Benign Prostatic Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction
- Trial name
- NCT02667938
- Testing
- HCP1303 capsule 5/0.2mg, HCP1303 capsule 5/0.4mg, HGP1201
- Volunteers
- 510 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Prostatic Hyperplasia
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
This will be an open-label, three-period, fixed-sequence study to evaluate the drug-drug interaction, pharmacokinetics and safety of dutasteride and tamsulosin when administered alone and in-combination in Chinese healthy male…
- Trial name
- NCT01957189
- Testing
- Dutasteride and Tamsulosin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom…
- Trial name
- NCT02244320
- Testing
- Tamsulosin
- Volunteers
- 4,150 people
- Sponsor
- Boehringer Ingelheim
Prostatic Neoplasms
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the…
- Trial name
- NCT07082920
- Testing
- JNJ-78278343, JNJ-95298177, JNJ-87189401
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in…
- Trial name
- NCT00473512
- Testing
- Abiraterone acetate, Abiraterone acetate MTD, Dexamethasone
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Cougar Biotechnology, Inc.
Localized Prostate Cancer
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
The goal of this clinical trial is to evaluate the safety of the AQUABEAM Robotic System in treating patients with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.
- Trial name
- NCT06054867
- Testing
- Robotic Waterjet Treatment
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- PROCEPT BioRobotics
Lung Cancer (NSCLC), Prostate Cancer
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.
- Conditions
- Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
- Trial name
- NCT07181473
- Testing
- TJ101
- Where
- 7 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Phrontline Biopharma
Metastatic Castration-Resistant Prostate Cancer
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
Provide pre-approval single-patient Expanded Access (Compassionate Use) of talazoparib for patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05650476
- Testing
- Talazoparib
- Sponsor
- Pfizer
Prostatic Neoplasms
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with…
- Trial name
- NCT07906717
- Testing
- JNJ-101556143, Best Supportive Care
- Where
- 4 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Metastatic
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Phase 1b study to assess the combination of ARV-110 (bavdegalutamide) and abiraterone in participants with metastatic prostate cancer with rising PSA values on abiraterone.
- Trial name
- NCT05177042
- Testing
- Bavdegalutamide, Abiraterone
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 45 people
- Sponsor
- Arvinas Androgen Receptor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.